SANTHOSH AMBIKA MD NPI 1174747323

NPI Details

Santhosh Ambika, MD is a hematology and oncology internal medicine in Reno, NV with 25 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Santhosh Ambika, MD NPI is 1174747323. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

5423 RENO CORPORATE DR.
RENO, NV
ZIP 89511-250
Phone: (775) 329-0873
Fax: (775) 329-1026

The NPI 1174747323 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg (HCPCS:Q5107)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, decitabine, 1 mg (HCPCS:J0894)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, bortezomib, not otherwise specified, 0.1 mg (HCPCS:J9044)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, pegfilgrastim-cbqv, biosimilar, (udenyca), 0.5 mg (HCPCS:Q5111)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Unclassified drugs (HCPCS:J3490)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Ferritin (blood protein) level (HCPCS:82728)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Iron level (HCPCS:83540)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Iron binding capacity (HCPCS:83550)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Urinalysis, manual test (HCPCS:81002)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Injection of drug or substance into vein (HCPCS:96374)
• Magnesium level (HCPCS:83735)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Red blood count, automated test (HCPCS:85045)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Uric acid level, blood (HCPCS:84550)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Phosphate level (HCPCS:84100)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Thyroid hormone, t3 measurement, total (HCPCS:84480)

The enumeration date for this NPI number is 4/12/2007 and was last updated on 5/22/2019.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.